On Friday, the U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s PFE and Astellas Pharma Inc.’s ALPMF ALPMY ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...

The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...

Dr. Stéphanie Gaillard and Dr. Bill Tew share updates to the evidence-based guideline on neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer. They highlight recommendations across ...

Neoadjuvant cisplatin-based chemotherapy plus chemoradiotherapy offers a safe, effective bladder-sparing approach with promising long-term outcomes in nonmetastatic MIBC. Median disease-free survival ...

Neoadjuvant chemotherapy with a regimen of gemcitabine-cisplatin for high-risk upper tract urothelial carcinoma (UTUC) resulted in a high rate of downstaging, and should now be considered a new ...

The addition of atezolizumab to standard neoadjuvant chemotherapy followed by adjuvant atezolizumab did not significantly improve event-free survival (EFS) in patients with stages II-III ...

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant chemotherapy significantly lowered 90-day postoperative mortality for advanced ovarian cancer across ...

Ahead of the study's publication, the data was shared at the 2026 European Society for Medical Oncology Gastrointestinal ...